Araştırma Çıktıları

Permanent URI for this communityhttps://hdl.handle.net/11443/931

Browse

Author: search.filters.author.Dundar, Munis

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    COVID-19 vaccine candidates and vaccine development platforms available worldwide
    (ELSEVIER, 2021-01-01) Duman, Nilgun; ALzaidi, Zahraa; Aynekin, Busra; Taskin, Duygu; Demirors, Busra; Yildirim, Abdulbaki; Sahin, Izem Olcay; Bilgili, Faik; Turanli, Eda Tahir; Beccari, Tommaso; Bertelli, Matteo; Dundar, Munis
    The pandemic caused by the worldwide spread of the coronavirus, which first appeared in 2019, has been named coronavirus disease 19 (COVID-19). More than 4.5 million deaths have been recorded due to the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to the World Health Organization. COVID-19 Dashboard in September 2021. Apart from the wildtype, other variations have been successfully transmitted early in the outbreak although they were not discovered until March 2020. Modifications in the SARS-CoV-2 genetic material, such as mutation and recombi-nation, have the ability to modify the viral life span, along with transitivity, cellular tropism, and symptom severity. Several processes are involved in introducing novel vaccines to the population, including vaccine manufacturing, preclinical studies, Food and Drug Administration permission or cer-tification, processing, and marketing. COVID-19 vaccine candidates have been developed by a number of public and private groups employing a variety of strategies, such as RNA, DNA, protein, and viral vectored vaccines. This comprehensive review, which included the most subsequent evidence on unique features of SARS-CoV-2 and the associated morbidity and mortality, was carried out using a systematic search of recent online databases in order to generate useful knowledge about the COVID-19 updated versions and their consequences on the disease symptoms and vaccine development. (c) 2021 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
  • Thumbnail Image
    Item
    Evaluation of aortic intima-media thickness in newborns with Down syndrome
    (WROCLAW MEDICAL UNIV, 2017-01-01) Sarici, Dilek; Kurtoglu, Selim; Sarici, Serdar Umit; Yikilmaz, Ali; Akin, Mustafa Ali; Gunes, Tamer; Ozturk, Mehmet Adnan; Narin, Nazmi; Dundar, Munis; Serdar, Muhittin
    Background. Health care programs for children with Down syndrome (DS) help improve the overall outcome and quality of life of these children. It is therefore very important to focus on the most common and serious problems of these patients, such as congenital heart defects and cardiac problems, and to keep medical guidelines updated with regard to these problems. Objectives. The aim of this study was to evaluate aortic intima-media thickness (aIMT), lipid profiles and blood pressure in DS patients in comparison with a control group of age-and gender-matched neonates without DS. Material and methods. Serum concentrations of lipids (total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride), blood pressure and abdominal aIMT were measured in newborns with DS, and compared with the measurements from age-and gender-matched newborns without DS. Results. No statistically significant differences between the 2 groups of newborns were detected with respect to aIMT, lipid levels or blood pressure. Conclusions. This study represents the first investigation of aIMT - one of the most important indicators of atherosclerosis - in DS patients, but neither a significantly increased aIMT, nor any significant changes in lipid profiles or blood pressure were detected in this group of patients. Whether aIMT differs according to the type of congenital heart defect (such as atrial septal defect, ventricular septal defect, patent ductus arteriosus, and atrioventricular septal defect) among DS patients remains to be determined in future studies.